Recherche
Plasticité phénotypique et génétique du cancer : Ch. Theillet/C. Sardet

Liste des Publications

Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier M, Goncalves A, Dalenc F, Deluche E, Fresnel J, Augereau P, Ferrero J, Geffrelot J, Fumet J-D, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur. J. Cancer. 2020;125. doi:10.1016/j.ejca.2019.11.001

Hayek S, Pietrancosta N, Hovhannisyan A, Alves de Sousa R, Bekaddour N, Ermellino L, Tramontano E, Arnould S, Sardet C, Dairou J, Diaz O, Lotteau V, Nisole S, Melikyan G, Herbeuval J-P, Vidalain P-O Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition. Eur J Med Chem. 2020;186. doi:10.1016/j.ejmech.2019.111855

Pomel C, Lecuru F, Leblanc E, Mathevet P, Colombo P-E, Collinet P, Nadeau C, Huchon C, Chereau E, Lambaudie E, Ferry P, Rafii A, Rouzier R [Minimal invasive surgery for early stage cervical cancer. Recommendations from the GINECO surgeon's group]. Bull Cancer. Jul 25, 2019. doi:10.1016/j.bulcan.2019.05.010

Bakrin N, Classe J, Colombo P, Ferron G, Freyer G, Glehen O, Gouy S, Huchon C, Narducci F, Pocard M, Pomel C, Rouzier R [CHIP and ovarian cancer]. Gynecol Obstet Fertil Senol. Jun 26, 2019. doi:10.1016/j.gofs.2019.06.007

Roux P, Knight S, Cohen M, Classe J, Mazouni C, Chauvet M-P, Reyal F, Colombo P-E, Jouve E, Chopin N, Daraï E, Coutant C, Lambaudie E, Houvenaeghel G Tubular and mucinous breast cancer: results of a cohort of 917 patients. 2019;105(1):55-62. doi:10.1177/0300891618811282

von Minckwitz G, Huang C-S, Mano M, Loibl S, Mamounas E, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer H, Jacot W, Conlin A, Arce-Salinas C, Wapnir I, Jackisch C, DiGiovanna M, Fasching P, Crown J, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam L, Tesarowski D, Smitt M, Douthwaite H, Singel S, Geyer C Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med.. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017

Darlix A, Hirtz C, Thezenas S, Maceski A, Gabelle A, Lopez-Crapez E, Firmin N, Guiu S, Jacot W, Lehmann S The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019;19(1):110. doi:10.1186/s12885-019-5287-z

Chartron E, Theillet C, Guiu S, Jacot W Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Crit. Rev. Oncol. Hematol.. 2019;133. doi:10.1016/j.critrevonc.2018.10.012

Carayol M, Ninot G, Senesse P, Bleuse J-P, Gourgou S, Sancho-Garnier H, Sari C, Romieu I, Romieu G, Jacot W Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial. BMC Cancer. 2019;19(1):737. doi:10.1186/s12885-019-5896-6

Carrier G, Rouanet P, Colombo P Robotic colon resection for splenic flexure cancer with intracorporeal anastomosis (with video). J Visc Surg. Jul 16, 2019. doi:10.1016/j.jviscsurg.2019.06.013

Jacot W, Heudel P-E, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Courtinard C, Cottu P, Robain M, Mailliez A Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int. J. Cancer. May 14, 2019. doi:10.1002/ijc.32402

Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Landas E, Bleuse J-P, Chardès T, Prost J-F, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Br. J. Cancer. Dec 03, 2019. doi:10.1038/s41416-019-0670-8

Vasseur A, Cabel L, Tredan O, Chevrier M, Dubot C, Jacot W, Goncalves A, Debled M, Levy C, Ferrero J-M, Jouannaud C, Luporsi E, Mouret-Reynier M-A, Dalenc F, Savignoni A, Tanguy M-L, Pierga J-Y Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). Angiogenesis. Nov 26, 2019. doi:10.1007/s10456-019-09697-7

Souche R, Coignac A, Dupuy M, Bertrand M, Raingeart I, Guiu B, Herrero A, Panaro F, Portales F, Ramos J, Colombo P-E, Prudhomme M, Assenat E, Fabre J-M Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients. Clin Res Hepatol Gastroenterol. Sep 19, 2019. doi:10.1016/j.clinre.2019.08.010

Cabel L, Carton M, Cheaib B, Pierga J-Y, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. Breast Cancer Res. Treat.. 2019;173(2):397-406. doi:10.1007/s10549-018-5017-2

Houvenaeghel G, de Nonneville A, Cohen M, Classe J-M, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo P-E, Gimbergues P, Chauvet M-P, Azuar A-S, Rouzier R, de Lara C, Muracciole X, Agostini A, Lambaudie E Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. Breast Cancer Res. Treat.. 2019;173(1):111-122. doi:10.1007/s10549-018-4944-2

Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier M, Goncalves A, Dalenc F, Delaloge S, Campone M, Augereau P, Ferrero J, Levy C, Fumet J-D, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, Pasquier D, Bachelot T Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br. J. Cancer. 2019;121(12):991-1000. doi:10.1038/s41416-019-0619-y

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Papadakos K, Darlix A, Jacot W, Blom A High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker. Front Oncol. 2019;9. doi:10.3389/fonc.2019.01141

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer J-C, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. Clin. Pharmacol. Ther.. Feb 20, 2019. doi:10.1002/cpt.1404

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin J, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E ERR? promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene. 2019;38(7):950-964. doi:10.1038/s41388-018-0579-3

Fonti C, Saumet A, Abi-Khalil A, Orsetti B, Cleroux E, Bender A, Dumas M, Schmitt E, Colinge J, Jacot W, Weber M, Sardet C, du Manoir S, Theillet C Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells. Int. J. Cancer. 2019;145(5):1299-1311. doi:10.1002/ijc.32413

Alexandre M, Maran-Gonzalez A, Viala M, Firmin N, D'Hondt V, Gutowski M, Bourgier C, Jacot W, Guiu S Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?. Cancer Manag Res. 2019;11. doi:10.2147/CMAR.S221676

Paul C, Delpech H, Haouzi D, Hamamah S, Sardet C, Fabbrizio E Coprs inactivation leads to a derepression of LINE1 transposons in spermatocytes. FEBS Open Bio. 2019;9(1):159-168. doi:10.1002/2211-5463.12562

Scholl S, Popovic M, de la Rochefordiere A, Girard E, Dureau S, Mandic A, Koprivsek K, Samet N, Craina M, Margan M, Samuels S, Zijlmans H, Kenter G, Hillemanns P, Dema S, Dema A, Malenkovic G, Djuran B, Floquet A, Garbay D, Guyon F, Colombo P, Fabbro M, Kerr C, Ngo C, Lecuru F, Campo E, Coutant C, Marchal F, Mesgouez-Nebout N, Fourchotte V, Feron J, Morice P, Deutsch E, Wimberger P, Classe J-M, Gleeson N, von der Leyen H, Minsat M, Dubot C, Gestraud P, Kereszt A, Nagy I, Balint B, Berns E, Jordanova E, Saint-Jorre N, Savignoni A, Servant N, Hupe P, de Koning L, Fumoleau P, Rouzier R, Kamal M Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. EBioMedicine. 2019;43. doi:10.1016/j.ebiom.2019.03.069



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés